#United States #CARY #OncoHost #AI Excellence #PROphet platform

OncoHost Clinches 2026 Artificial Intelligence Excellence Award

OncoHost, a pioneering company in precision oncology driven by artificial intelligence, has proudly announced its victory in the 2026 Artificial Intelligence Excellence Awards, specifically in the health category. This impressive recognition underscores the profound influence OncoHost is having on clinical decision-making within the oncology sector through cutting-edge proteomic analysis and sophisticated machine learning techniques.

The Artificial Intelligence Excellence Awards, presented by the Business Intelligence Group, honor organizations that employ AI solutions in ways that generate tangible, measurable impacts across various industries. These awards spotlight the organizations and individuals at the forefront of driving AI from mere experimental stages into accountable, real-world implementations.

OncoHost's award-winning platform, PROphet®, epitomizes this commitment to innovation. This state-of-the-art machine learning solution leverages comprehensive analysis of host-response biology to forecast outcomes for patients undergoing immunotherapy. By amalgamating high-dimensional plasma proteomics with explainable AI, PROphet® delivers pertinent clinically actionable insights to individuals newly diagnosed with cancer. This equips oncologists with the information needed to make more informed, data-driven treatment decisions, effectively reducing patient exposure to ineffective therapies and enhancing overall treatment efficacy.

As articulated by Russ Fordyce, Chief Recognition Officer of the Business Intelligence Group, “2026 is about execution, accountability, and results,” emphasizing that OncoHost's accomplishments resonate with the market's shift towards practical AI that genuinely addresses healthcare challenges. He noted that the recognition showcases OncoHost as not just a participant in the AI evolution but as an entity that is shaping the future of AI in healthcare.

Dr. Ofer Sharon, the CEO of OncoHost, commented, “Being recognized in the 2026 Artificial Intelligence Excellence Awards reflects the strength of our strategic vision and the real-world impact of our technology.” He elaborated on the company’s focus on redefining precision medicine, noting that by introducing clinically actionable and comprehensible AI into routine oncology practice, OncoHost is setting new benchmarks for AI trust and usage in healthcare.

The PROphet® platform signifies a significant breakthrough in oncology AI, marking a departure from traditional, tumor-focused models and integrating systemic immune responses for comprehensive patient insight. With the analysis of over 7,000 proteins from each patient, PROphet® is validated through numerous peer-reviewed studies, showcasing robust predictive performance in practical settings. Its increasing adoption across roughly 200 cancer centers in the United States and its usage by scores of oncologists indicate its critical role in the everyday practices of cancer treatment.

OncoHost, headquartered in the dual locations of Binyamina, Israel, and Cary, North Carolina, is at the forefront of changing the landscape of precision medicine for improved patient outcomes. Its flagship offering, PROphetNSCLC®, aids in first-line treatment decisions for metastatic non-small cell lung cancer (NSCLC) by providing clinical insights that extend beyond conventional tumor-only biomarkers.

As noted, since its inception in 2013, the Artificial Intelligence Excellence Awards have been key in recognizing those harnessing AI technology to resolve real-world problems. Over the years, they have evaluated advancements across numerous AI applications and industries, celebrating innovations that enhance human experiences and advance societal progress. Award recipients are determined by an experienced panel of business leaders, honoring those making meaningful, beneficial contributions through the use of AI.

OncoHost’s outstanding achievement in receiving the 2026 Artificial Intelligence Excellence Award speaks volumes about its commitment to pioneering advancements in cancer treatment, ultimately aiming to refine patient outcomes through innovative technologies. This accolade amplifies OncoHost's reputation as a leader in the intersection of AI and healthcare, and a testament to what can be achieved with visionary leadership and technological prowess.